Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Elicio Therapeutics ( (ELTX) ).
On March 16, 2026, Elicio Therapeutics entered into a new at-the-market equity offering program of up to $100 million in common stock through B. Riley Securities, JonesTrading Institutional Services and Ladenburg Thalmann, giving the biotech flexibility to raise capital over time on The Nasdaq Capital Market or other trading venues while paying the agents a 3% commission on gross proceeds. The company is not obligated to sell shares and can terminate the arrangement on short notice, signaling a desire to maintain funding optionality without committing to immediate dilution.
Also on March 16, 2026, Elicio terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had allowed up to $40 million of at-the-market issuance, with Jones waiving notice periods so the termination was effective immediately and imposed no penalties. Following this termination, Elicio may no longer issue shares under the earlier JonesTrading facility, effectively consolidating its equity-raising activities under the new, larger $100 million program.
The most recent analyst rating on (ELTX) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Elicio Therapeutics stock, see the ELTX Stock Forecast page.
Spark’s Take on ELTX Stock
According to Spark, TipRanks’ AI Analyst, ELTX is a Neutral.
The score is primarily held down by weak financial performance (zero revenue, ongoing losses, heavy cash burn, and a leveraged/fragile balance sheet). Technicals provide partial support with price trading above key moving averages and neutral momentum, while valuation remains constrained by a negative P/E and no dividend yield.
To see Spark’s full report on ELTX stock, click here.
More about Elicio Therapeutics
Elicio Therapeutics, Inc. is a biotechnology company that develops therapeutic products and operates in the life sciences sector, with its common stock listed on The Nasdaq Capital Market and funded in part through public equity offerings to support its business activities and growth plans.
Average Trading Volume: 129,196
Technical Sentiment Signal: Buy
Current Market Cap: $224.4M
Find detailed analytics on ELTX stock on TipRanks’ Stock Analysis page.